With industry experts predicting sales of GLP-1 agonists (glucagon-like peptide 1 agonists) to reach $50 billion by the decade’s end, various pharmaceutical companies are looking to seize their share of this lucrative market. However, the road to unlocking the full potential of these drugs in treating chronic conditions is paved with obstacles.
The full potential of GLP-1 agonists can be realized by transforming perspectives of patients, healthcare professionals, payers, and the pharmaceutical industry. We’ve gathered several experts from across OPEN Health to provide their take on the major challenges faced by key stakeholders and how these challenges could be approached to forge a successful path forward.
“ The use of GLP-1 agonists is rapidly evolving. As new agents and dosing options come to market, pharma companies will need to be agile in their thinking and approach to maximize access and outcomes for patients. With a range of experts across medical affairs, market access, commercialization, HEOR, and patient engagement, OPEN Health is uniquely suited to partner with our clients to achieve these goals.”
Annemarie Clegg, MD
Chief Medical Officer
